CN107281323A - Purposes of the black fruit fructus lycii powder in anti-trioxypurine or treatment gout product is prepared - Google Patents
Purposes of the black fruit fructus lycii powder in anti-trioxypurine or treatment gout product is prepared Download PDFInfo
- Publication number
- CN107281323A CN107281323A CN201710686418.6A CN201710686418A CN107281323A CN 107281323 A CN107281323 A CN 107281323A CN 201710686418 A CN201710686418 A CN 201710686418A CN 107281323 A CN107281323 A CN 107281323A
- Authority
- CN
- China
- Prior art keywords
- medicine
- food
- health products
- fructus lycii
- black fruit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000013399 edible fruits Nutrition 0.000 title claims abstract description 38
- 239000000843 powder Substances 0.000 title claims abstract description 37
- 201000005569 Gout Diseases 0.000 title claims abstract description 35
- 239000003814 drug Substances 0.000 claims abstract description 52
- 235000013305 food Nutrition 0.000 claims abstract description 30
- 230000036541 health Effects 0.000 claims abstract description 30
- 210000004369 blood Anatomy 0.000 claims abstract description 15
- 239000008280 blood Substances 0.000 claims abstract description 15
- 201000001431 Hyperuricemia Diseases 0.000 claims abstract description 12
- 230000002265 prevention Effects 0.000 claims abstract description 10
- 229940079593 drug Drugs 0.000 claims description 15
- 102000004889 Interleukin-6 Human genes 0.000 claims description 12
- 108090001005 Interleukin-6 Proteins 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 229940100601 interleukin-6 Drugs 0.000 claims description 12
- 230000001154 acute effect Effects 0.000 claims description 8
- 239000002245 particle Substances 0.000 claims description 8
- 108010093894 Xanthine oxidase Proteins 0.000 claims description 7
- 102100033220 Xanthine oxidase Human genes 0.000 claims description 7
- 108010074051 C-Reactive Protein Proteins 0.000 claims description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 3
- 230000008859 change Effects 0.000 claims description 3
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 claims description 3
- 102000010906 Cyclooxygenase 1 Human genes 0.000 claims description 2
- 108010037464 Cyclooxygenase 1 Proteins 0.000 claims description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 102100032752 C-reactive protein Human genes 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 abstract description 14
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 abstract description 11
- 229940116269 uric acid Drugs 0.000 abstract description 11
- 238000011160 research Methods 0.000 abstract description 4
- 239000000047 product Substances 0.000 description 24
- 230000000694 effects Effects 0.000 description 13
- 238000005259 measurement Methods 0.000 description 11
- 210000004185 liver Anatomy 0.000 description 10
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 8
- 210000003734 kidney Anatomy 0.000 description 8
- 206010042674 Swelling Diseases 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 230000008961 swelling Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 230000009467 reduction Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 4
- 238000002224 dissection Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 229960000905 indomethacin Drugs 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000002604 ultrasonography Methods 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000001543 one-way ANOVA Methods 0.000 description 3
- 239000008227 sterile water for injection Substances 0.000 description 3
- 244000025254 Cannabis sativa Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 244000241838 Lycium barbarum Species 0.000 description 2
- 235000015459 Lycium barbarum Nutrition 0.000 description 2
- 235000015468 Lycium chinense Nutrition 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- RYYCJUAHISIHTL-UHFFFAOYSA-N 5-azaorotic acid Chemical compound OC(=O)C1=NC(=O)NC(=O)N1 RYYCJUAHISIHTL-UHFFFAOYSA-N 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 206010070968 Disorders of purine metabolism Diseases 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108700012920 TNF Proteins 0.000 description 1
- 208000005485 Thrombocytosis Diseases 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 208000026816 acute arthritis Diseases 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229960002708 antigout preparations Drugs 0.000 description 1
- 239000003637 basic solution Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000003150 biochemical marker Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 210000003284 horn Anatomy 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- NAFSTSRULRIERK-UHFFFAOYSA-M monosodium urate Chemical compound [Na+].N1C([O-])=NC(=O)C2=C1NC(=O)N2 NAFSTSRULRIERK-UHFFFAOYSA-M 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229950000193 oteracil Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000012372 quality testing Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 235000020795 whole food diet Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides the purposes the invention provides black fruit fructus lycii powder in the food, medicine or health products of anti-trioxypurine is prepared.Present invention research is found, blood uric acid can be effectively reduced using black fruit fructus lycii powder, treats gout, is that clinical prevention or/and treatment hyperuricemia or gout provide new product.
Description
Technical field
The present invention relates to the new application of black fruit fructus lycii.
Background technology
Gout (gout) is that long-term disorders of purine metabolism, blood uric acid increase one group of different substantiality disease for causing tissue damage.
Clinical characters be hyperuricemia (hyperuricemia, HUA), gouty acute arthritis recurrent exerbation, tophaceous deposition,
Characteristic chornic arthritis and joint deformity, often involve kidney and cause arteriosclerotic kidney and kidney calculus urate to be formed.Gout
Biochemical marker be hyperuricemia, refer to extracellular fluid lithate be in over-saturation state.Lithate (monosodium urate
Crystal, MSU) deposit to cause a series of acute inflammatory reactions in crystalline form in joint and periarticular tissue, be
Gout.It is generally acknowledged that Xue Niao Suan≤416 μm ol/L are hyperuricemia, and about 5%-12% Patients with Hyperuricemia can develop
As gout, the chance that serum uric acid level continues to have 70%-90% in 540 μm of ol/L persons obtains gout, so reduction blood uric acid is
We prevent and treated the basic solution of gout.
According to《Chinese medicinal application detection》Statistics, current China's Patients with Hyperuricemia number is up to 1.2 hundred million, and by high lithemia
The disease rates that mass formed by blood stasis develops into gout are about 1/10.China's gout number of the infected is in 2015 up to 75,000,000, and gout is sent out
Sick rate also significantly rises with 7.5% speed every year, and 1/5 gout patients have lost viability, the gout patients course of disease
More than 10 years, easily trigger and be difficult to the uremia cured, heavy psychological pressure and financial burden are brought to patient and family.It is high
The disease such as uricacidemia and primary gout and obesity, hyperlipidemia, high blood pressure, diabetes, coronary heart disease is in notable positive
Close.Therefore, gout is a kind of serious metabolic disease for endangering human health especially as diabetes.
For the treatment of acute stage gout, clinical medicine mainly from non-steroid anti-inflammatory drug (NASIDs), colchicin,
Cortex hormone of aadrenaline and antalgesic these four medicines.However, although the effect of these medicine anti-inflammatory analgetics is fast, medical expense
Height, and most drug toxic side effect is quite obvious.
If can find wholefood is used to treat gout, the generation of toxic side effect can will be to greatest extent reduced.
The content of the invention
Based on above-mentioned present situation, the present invention intends providing medical usage of the black fruit fructus lycii powder in terms of high lithemia.
Specifically, the use the invention provides black fruit wolfberry fruit powder in the food, medicine or health products of anti-trioxypurine is prepared
On the way.
The particle diameter of black fruit fructus lycii powder of the present invention is 200~500 mesh.In an embodiment of the invention, preferably
The particle diameter used is 300~500 mesh.
The cell dia of Chinese medicine (plant) is generally at 10-200 μm or so, and the particle diameter of its Ultramicro-powder can be typically crushed to carefully
Born of the same parents' particle diameter is the powder of 48 μm (300 mesh)~25 μm (500 mesh), is drunk during some are even water-soluble.The powder of 200 mesh or so
End, particle diameter is about 70.9-79.1 μm.
Further, the food, medicine or health products be prevention or/and treat the food of hyperuricemia, medicine or
Health products.
Further, the food, medicine or health products are prevention or/and food, the medicine for the treatment of high lithemia associated diseases
Product or health products.
Further, the high lithemia associated diseases are gout.
Further, the food, medicine or health products are food, medicine or the health products for suppressing xanthine oxidase.
Present invention also offers purposes of the black fruit fructus lycii powder in food, medicine or the health products for preparing treatment gout.This
The particle diameter for inventing the black fruit fructus lycii powder is 200~500 mesh.In an embodiment of the invention, the particle diameter preferably used
For 300~500 mesh.
Further, the food, medicine or health products are prevention or/and the food, medicine or the guarantor that treat acute gout
Strong product.
Wherein, the food, medicine or health products are hs-CRP, tumor necrosis factor α, epoxy in reduction blood
Food, medicine or the health products of the content of at least one of synthase 1, prostaglandin E.
Wherein, it was unexpectedly observed that in the influence to inflammatory factor, the action effect of black fruit fructus lycii powder is nearly all in experiment
Not as positive control medicine Indomethacin；But, the reduction to interleukin-6 is acted on, and black fruit fructus lycii powder is in middle dosage and high dose
Under effect, better than Indomethacin, black fruit fructus lycii powder will be substantially better than positive control medicine in the inhibitory action to interleukin-6.
Interleukin-6, abbreviation interleukin 6 (IL-6), is a kind of cell factor, belongs to one kind of interleukins.It
It is by fibroblast, Monocytes/Macrophages, T lymphocytes, bone-marrow-derived lymphocyte, epithelial cell, horn cell and a variety of knurls
Produced by cell.IL-1, TNF-a, PDGF, virus infection, double-stranded RNA and c AMP etc., it can induce normal cell and produce white be situated between
Element 6.Interleukin 6, which can be stimulated, to be participated in the cell propagation of immune response, breaks up and improve its function.It has now been discovered that white be situated between
The abnormal rise of element 6, often has close association, such as thrombocythemia, diseases associated with inflammation, immune response are different with multiple physical body disease
Often, osteoporosis, chronic joint rheumatism, hypercalcemia, Huppert's disease, cachexia, ephritis etc., it can participate in inflammatory reaction
And exothermic reaction.Therefore, the significant inhibitory action of interleukin-6 is being prepared present invention also offers it based on black fruit fructus lycii powder
Purposes in interleukin-6 inhibitor.
Found in acute gout measuring foot swelling result, using black fruit fructus lycii powder middle dosage and high dose (1~
When 2g/kg), in 72h, the therapeutic effect to acute gout is suitable with positive drug Indomethacin effect, and this result exceeds
The expectation of inventor.
Further, the black fruit fructus lycii powder daily dosage is scaled rat dosage for 1~2g/kg；Experiment shows,
Under 1g/kg and 2g/kg dosage, its therapeutic effect is similar, therefore can preferably 1g/kg.
Present invention research is found, blood uric acid can be effectively reduced using black fruit fructus lycii powder, is treated gout, is clinical prevention
Or/and treatment hyperuricemia or gout provide new product；Also, during treatment gout, it can send out after 72 hours
The activity suitable with positive drug is waved, and in the inhibitory action to interleukin-6, black fruit fructus lycii powder has been even more than positive drug
Thing, achieves unexpected good result.
The raw material that the present invention is used is edible natural plants fruit, compared to known gout medicine, also with malicious secondary work
With low advantage, patient compliance is more preferable.
Based on above-mentioned discovery, anti-trioxypurine or/and treatment are being prepared present invention also offers the product containing black fruit fructus lycii powder
Purposes in food, medicine or the health products of gout.
Wherein, the food, medicine or health products be prevention or/and treat the food of hyperuricemia, medicine or
Health products.
Wherein, the food, medicine or health products are that prevention or/and treatment xanthine oxidase increase associated diseases extremely
Food, medicine or health products.
Active component in above-mentioned " product " at least includes black fruit fructus lycii powder one kind, it is of course also possible to only with black fruit
Wolfberry fruit powder is active component.In addition, related auxiliary material or complementary composition can also be included in the product.
The product is given by intestines and stomach absorption features, and different preparation types can be prepared according to the actual requirements,
Such as liquid form, solid form.Based on different preparation types, different auxiliary materials can be selected.
Brief description of the drawings
Fig. 1 foot swelling measurement results, wherein, L1=low dose groups, L2=middle dose groups, L3=high dose groups, with blank
Group does variance analysis, P** for reference group<0.01 is extremely notable, p*<0.05 is notable.
Fig. 2 mouse changes of serum uric acid results, wherein, 0.5=low dose groups, 1=middle dose groups, 2=high dose groups, with sky
Bai Zuwei reference groups do variance analysis, P**<0.01 is extremely notable, p*<0.05 is notable；Variance is done by reference group of model group
Analysis, P##<0.01 is extremely notable, P#<0.05 is notable.
Embodiment
With reference to specific embodiment, the present invention is further elaborated, but the present invention does not limit to and following examples,
The raw material can be obtained from open commercial sources unless otherwise specified.
Test 1 pair of pain wind action
1. sample preparation
Ultra micro fruit powder:After black fruit fructus lycii is dried, ultramicro grinding obtains the mesh powder of 300 mesh~500.
2. experimental animal
Rat:SD kinds, SPF grades of 180-200g, male sells unit:Hunan SJA Laboratory Animal Co. , Ltd,
Quality testing unit:Hunan SJA Laboratory Animal Co. , Ltd, sells unit credit number:SCXK (Hunan) 2013-
0004, experimental unit's licensing numbering:SYXK (green grass or young crops) 2012-0001
3. rat acute Gout Model pharmacological research experimental method
Animal packet:Adaptability is raised one week after packet, is divided into 6 groups, and each group 10 is respectively:Blank group, model group,
Positive drug group, the low middle high dose group of test specimen is 3 groups, amounts to 6 groups
Sample:Black fruit fructus lycii Ultramicro-powder is formulated as 30g/100ml, and ultrasound 10min, low middle height with sterilized water for injection
Dosage group is respectively 0.5g/kg, 1g/kg, 2g/kg, i.e., gavage 0.35ml respectively, 0.7ml are every daily to give before 1.4ml. is determined
Medicine, positive drug is identical.
Acute gout derivant MSU:40mg/ml, and ultrasound 10min are formulated as with 0.9%NaCl, in the sufficient foot pad of Rat Right
Intracutaneous injection 0.1ml
Positive drug:Indomethacin is formulated as 50mg/100ml with 0.9%NaCl, is administered by 3mg/kg, 1.2ml is filled,
Use preceding ultrasonic 10min
Foot swelling is determined:Every group of Rat Right metapedes thickness is determined with electronic vernier caliper by a people respectively, is determined respectively
Right metapedes thickness after 0h, 4h, 24h, 48h, 72h
Exoculation pearl takes blood and the execution that dislocates after observation 72h, and 12h fasting be can't help taking liver after water, dissection before putting to death, spleen, kidney, right
Metapedes
Blood:Take blood room temperature to place after 2h takes supernatant 3000r centrifugations 5min to take serum to be put into -80 after 2000r centrifugations 5min
DEG C standby of refrigerator
Liver, spleen, kidney, right metapedes:Dissection, takes liver, spleen, kidney, right metapedes after physiological saline Rapid Cleaning two times, uses yarn
Cloth absorbs water, and is put into valve bag after weighing, is put into the standby of -80 DEG C of refrigerators
4 result of the tests
4.1 foot swelling measurement results
Data are with 10 rat paw edemas in Fig. 1Variance analysis is carried out with one-way anova.By scheming
Understand：0h each group Rat Right metapedes measurement results illustrate that the right metapedes thickness of each group mouse is basically identical without significant difference, are surveyed after 4h
Determine the right metapedes thickness of result display model group significantly to increase and change little in 72, illustrate our modeling successes；It is positive after 4h
Foot swelling, which just occurs, in the property right metapedes of medicine to be significantly reduced, and middle dose group foot swelling occurs with high dose group in 48h to be significantly reduced, just
Walk and determine that middle dose group and high dose group have conspicuousness effect, and it is little by the known middle high dose group difference of figure.
4.2 inflammatory factors evaluate antigout effect
Table 1
Note：Variance analysis, P** are done by reference group of model group<0.01 is extremely notable, p*<0.05 is notable.
Data are determined with 10 rat blood serums in upper tableVariance analysis is carried out with one-way anova.By
Upper table result understands that high dose group is compared with model group with significant difference during the measurement result of hs-CRP is shown,
And middle high dose group difference is little；The measurement result of TNFa, which shows that low middle high dose group is compared with model group, all to be had
There is significant difference, and reduced into dosage correlation, but the difference between middle high dose group is far smaller than between low middle dosage
Difference；High dose group is compared with model group during the measurement result of interleukin-6 is shown all has significant difference, and middle height
Dosage group difference is little；The measurement result of cyclooxygenase 1, which shows that low middle high dose group is compared with model group, all has conspicuousness poor
It is different, and difference between low middle dosage is far above the difference between middle high dose；The high agent in showing of the measurement result of prostaglandin E
Amount group is compared with model group all has significant difference, and middle high dose group difference is little.Biochemical Indexes knot in summary
Fruit analysis understands that optimal dose group is that middle dose group is 1g/kg.
Test the effect of 2 pairs of uric acid
1. sample preparation
2. ultra micro fruit powder:After black fruit fructus lycii is dried, ultramicro grinding obtains the mesh powder of 300 mesh~500.
3. experimental animal
Mouse:KM kinds, SPF grades of 18-22g, male sells unit:Hunan SJA Laboratory Animal Co. , Ltd, matter
Amount detection unit:Hunan SJA Laboratory Animal Co. , Ltd, sells unit credit number:SCXK (Hunan) 2013-0004,
Experimental unit's licensing numbering:SYXK (green grass or young crops) 2012-0001
3. mouse high lithemia model pharmacology research experiment method
Animal packet:Adaptability is raised one week after packet, is divided into 6 groups, and each group 10 is respectively:Blank group, model group,
Positive drug group, the low middle high dose group of test specimen is 3 groups, amounts to 6 groups
Sample is configured:All samples 1h before on-test is prepared, and black fruit fructus lycii Ultramicro-powder is prepared with sterilized water for injection
For 10g/100ml, using preceding ultrasonic 10min, low middle high dose group is respectively 0.5g/kg, and 1g/kg, 2g/kg is difference gavage
0.125ml,0.25ml,0.5ml.Before measure, per average daily administration, positive drug is identical.
High lithemia modeling agent:Oteracil Potassium, 1.5g/100ml and ultrasound 10min, gavage are configured with heat sterilization water for injection
Is injected intraperitoneally by 270mg/kg in preceding 1h
Positive drug:Allopurinol tablet is pressed into after powder, is configured 0.1g/100ml with sterilized water for injection, is used preceding ultrasound
10min. fills this medicine 10mg/kg, i.e. 0.25ml.
Observe to dislocate after administration 1h for the 7th day and put to death, water is can't help in 12h fasting before putting to death, and exoculation pearl takes liver after taking blood, dissection
Spleen kidney
Blood:Take blood room temperature to place after 2h takes supernatant 3000r centrifugations 5min to take serum to be put into -80 after 2000r centrifugations 5min
DEG C refrigerator is standby
Liver and spleen kidney:Dissection, takes liver and spleen kidney, after twice of physiological saline Rapid Cleaning, is absorbed water with gauze, is put into after weighing cold
Frozen pipe, is put into -80 DEG C of refrigerators standby
4 result of the tests
4.1 changes of serum uric acid results
Data are with 10 mouse foot swellings in Fig. 2Variance analysis is carried out with one-way anova.By scheming
We understand：Using blank group as reference, model group has significant difference, illustrates modeling success, positive drug group, and each dosage
Group also has significant difference, illustrates reduction blood uric acid effect significantly, using model group as reference, low dose group does not have conspicuousness poor
Different, middle high dose group has significant difference, so that it is determined that middle dose group has the effect of reduction blood uric acid with high dose group, and
It is little by the known middle high dose group difference of figure.
4.2 liver xanthine oxidase measurement results
The liver xanthine oxidase measurement result of table 2
Note：Variance analysis, P are done by reference of blank group##<0.001 is extremely notable, P#<0.005 is notable；With model group
Variance analysis, P** are done for reference group<0.001 is extremely notable, p*<0.005 is notable.
From upper table we：Using blank group as reference, model group has significant difference, illustrates modeling success, with mould
Type group is reference, and positive drug group, low middle high dose group all have significant difference, illustrate black fruit fructus lycii Ultramicro-powder to liver
Xanthine oxidase, which has, significantly inhibits effect.The measurement result of xanthine oxidase in comprehensive changes of serum uric acid result and liver
Understand, middle dose group can reach optimum efficiency for optimal group, i.e. 1g/kg dosage.
It the above is only the preferred embodiment of the present invention, it is noted that above-mentioned preferred embodiment is not construed as pair
The limitation of the present invention, protection scope of the present invention should be defined by claim limited range.For the art
For those of ordinary skill, without departing from the spirit and scope of the present invention, some improvements and modifications can also be made, these change
Enter and retouch and also should be regarded as protection scope of the present invention.
Claims (10)
1. purposes of the black fruit fructus lycii powder in the food, medicine or health products of anti-trioxypurine is prepared；The particle diameter of the black fruit fructus lycii powder
For 200~500 mesh；Preferably 300~500 mesh.
2. purposes according to claim 1, it is characterised in that：The food, medicine or health products are prevention or/and treatment
Food, medicine or the health products of hyperuricemia.
3. purposes according to claim 1 or 2, it is characterised in that：The food, medicine or health products be prevention or/and
Treat food, medicine or the health products of high lithemia associated diseases.
4. purposes according to claim 3, it is characterised in that：The high lithemia associated diseases are gout.
5. purposes according to claim 1, it is characterised in that：The food, medicine or health products are to suppress xanthine oxidase
Change food, medicine or the health products of enzyme.
6. purposes of the black fruit fructus lycii powder in food, medicine or the health products for preparing treatment gout；The grain of the black fruit fructus lycii powder
Footpath is 200~500 mesh；Preferably 300~500 mesh.
7. purposes according to claim 6, it is characterised in that：The food, medicine or health products are prevention or/and treatment
Food, medicine or the health products of acute gout.
8. the purposes according to claim 5 or 6, it is characterised in that：The food, medicine or health products are to reduce in blood to surpass
The food of the content of at least one of sensitive C-reactive protein, tumor necrosis factor α, interleukin-6, cyclooxygenase 1, prostaglandin E,
Medicine or health products.
9. the purposes according to claim 5 or 6, it is characterised in that：The black fruit fructus lycii powder daily dosage is scaled rat
Dosage is 1~2g/kg.
10. purposes of the black fruit fructus lycii powder in interleukin-6 inhibitor is prepared.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710686418.6A CN107281323B (en) | 2017-08-11 | 2017-08-11 | Application of lycium ruthenicum powder in preparation of uric acid reducing or gout treating products |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710686418.6A CN107281323B (en) | 2017-08-11 | 2017-08-11 | Application of lycium ruthenicum powder in preparation of uric acid reducing or gout treating products |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107281323A true CN107281323A (en) | 2017-10-24 |
| CN107281323B CN107281323B (en) | 2021-01-15 |
Family
ID=60105041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710686418.6A Active CN107281323B (en) | 2017-08-11 | 2017-08-11 | Application of lycium ruthenicum powder in preparation of uric acid reducing or gout treating products |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107281323B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107788194A (en) * | 2017-11-12 | 2018-03-13 | 张雅萍 | A kind of black fruit fructus lycii anti-trioxypurine functional gels candy and preparation method thereof |
| CN116549535A (en) * | 2023-06-28 | 2023-08-08 | 未名太研生物科技(绍兴)有限公司 | Uric acid-reducing ferment, preparation method and application thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20130136151A (en) * | 2012-06-04 | 2013-12-12 | 권태선 | Improving gout, reducing uric acid, solving hangover of functional fermented food and method for producing of the same, and kimchi, gochujang, doenjang, soy sauce produced thereof |
| CN103623301A (en) * | 2013-11-27 | 2014-03-12 | 许伟 | Traditional Chinese medicine for treating podagra |
| CN106668657A (en) * | 2017-03-03 | 2017-05-17 | 孙龙喜 | Beverage capable of lowering uric acid and lipid and preparation method of beverage |
| CN106975036A (en) * | 2017-05-05 | 2017-07-25 | 廖祝君 | A kind of compound deacidification tea and preparation method thereof |
-
2017
- 2017-08-11 CN CN201710686418.6A patent/CN107281323B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20130136151A (en) * | 2012-06-04 | 2013-12-12 | 권태선 | Improving gout, reducing uric acid, solving hangover of functional fermented food and method for producing of the same, and kimchi, gochujang, doenjang, soy sauce produced thereof |
| CN103623301A (en) * | 2013-11-27 | 2014-03-12 | 许伟 | Traditional Chinese medicine for treating podagra |
| CN106668657A (en) * | 2017-03-03 | 2017-05-17 | 孙龙喜 | Beverage capable of lowering uric acid and lipid and preparation method of beverage |
| CN106975036A (en) * | 2017-05-05 | 2017-07-25 | 廖祝君 | A kind of compound deacidification tea and preparation method thereof |
Non-Patent Citations (6)
| Title |
|---|
| LI J ,SHI M ,ET AL.: "Protective Effects of Fraction 4a of Polysaccharides Isolated from Lycium barbarum Against KBrO3-induced Renal Damage in Rats", 《FOOD & FUNCTION》 * |
| SUE-JING WU, ET.AL: "Antioxidant Activities of Some Common Ingredients of Traditional Chinese Medicine,Angelica sinensis, Lycium barbarum and Poria cocos", 《PHYTOTHERAPY RESEARCH》 * |
| TRABSA, HAYAT.: "Kinetics of Inhibition of Xanthine Oxidase by Lycium arabicum and its Protective Effect against Oxonate-Induced Hyperuricemia and Renal Dysfunction in Mice", 《TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH》 * |
| 孙晓红，等: "野生黑枸杞与普通红枸杞营养成分和相关活性物质的分析与评价", 《营养学报》 * |
| 张轲，等: "黑果枸杞对大鼠运动性肾缺血再灌注损伤的保护作用", 《首都体育学院学报》 * |
| 袁良东，等: "抗痛风胶囊质量鉴定与治疗急性痛风性关节炎作用", 《世界最新医学信息文摘》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107788194A (en) * | 2017-11-12 | 2018-03-13 | 张雅萍 | A kind of black fruit fructus lycii anti-trioxypurine functional gels candy and preparation method thereof |
| CN107788194B (en) * | 2017-11-12 | 2021-05-11 | 张雅萍 | Lycium ruthenicum murr uric acid-reducing functional gel candy and preparation method thereof |
| CN116549535A (en) * | 2023-06-28 | 2023-08-08 | 未名太研生物科技(绍兴)有限公司 | Uric acid-reducing ferment, preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107281323B (en) | 2021-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104001046A (en) | Oral traditional Chinese medicine preparation for treating urinary calculus and preparation method thereof | |
| CN107281323A (en) | Purposes of the black fruit fructus lycii powder in anti-trioxypurine or treatment gout product is prepared | |
| CN106728096A (en) | Pharmaceutical composition for treating rheumatism bone disease | |
| CN103877438B (en) | Traditional Chinese medicine preparation for treating gout and production method thereof | |
| CN109453342A (en) | A kind of Chinese medicine composition and application, preparation method, health food with joint protection effect | |
| CN104815318A (en) | Traditional Chinese medicine preparation for treating gout | |
| CN102430015B (en) | Traditional Chinese medicinal preparation for treating nephritis and uremia as well as preparation method thereof | |
| US20100316753A1 (en) | Formulations and methods for reducing abdominal fat and waist circumference | |
| CN107334778B (en) | Purposes of the lycium ruthenicum polysaccharide in preparation treatment gout product | |
| CN106215046A (en) | A kind of Chinese medicine treating acute gouty arthritis | |
| CN107375532A (en) | Black fruit fructus lycii extract is preparing the purposes in treating gout product | |
| WO2021169682A1 (en) | Traditional chinese medicine composition, and preparation method therefor and application thereof | |
| CN107467568A (en) | A kind of natural composition for preventing or treating gout and application thereof | |
| CN102139060B (en) | Chinese medicinal composition for treating acute urarthritis | |
| CN109481469A (en) | Application of the drug and colla carapacis et plastri testudinis of a kind of colla carapacis et plastri testudinis treatment gout in preparation treatment gout drug | |
| CN107468816A (en) | A kind of pharmaceutical composition for treating gout | |
| CN100355449C (en) | Chinese medicine composition for treating stomach pain and preparing method thereof | |
| CN104940813A (en) | Traditional Chinese medicine composition for treating cholelithiasis and cholecystitis, and preparation method thereof | |
| CN107496437B (en) | Black fruit fructus lycii is preparing the purposes in anti-trioxypurine product | |
| CN104606538A (en) | Traditional Chinese medicine health product for preventing and treating diabetes | |
| CN100546598C (en) | A kind of oral liquid of eliminating hydrops and promoting graft function | |
| CN107007652A (en) | Purposes of the Kangfuxin Liquid Combined with Chinese Herbal in the medicine for preparing treatment infertility | |
| CN105106773B (en) | A kind of Chinese medicine composition for treating gout | |
| CN102228512B (en) | Medicine for treating rheumatoid arthritis and preparation method thereof | |
| CN107441241A (en) | A kind of pharmaceutical composition of anti-trioxypurine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |